688091.SH
Shanghai Yizhong Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 36.02
+3.74%Oct 21, 2026, 12:45 UTC
Shanghai Allist Pharmaceuticals announced that its wholly owned subsidiary completed the first administration in the 0.5 mg/kg dose group of the Phase I trial of YXC-001.
Source:Oct 19, 2026, 11:59 UTC
Shanghai Yizhong completed the repurchase of 1.1641 million shares, equal to 0.56% of its total share capital, for RMB44.9233 million excluding transaction fees.
Source:Aug 25, 2026, 08:16 UTC
Shanghai Yizhong announced its H1 2026 results: revenue of 166 million yuan, up 3.45% year-on-year; net profit attributable to shareholders of 42.3036 million yuan, up 11.31% year-on-year.
Source:Aug 18, 2026, 11:12 UTC
Shanghai Yizhong received approval from China's National Medical Products Administration for the clinical trial of its investigational drug YXC-002 for non-small cell lung cancer.
Source:Aug 17, 2026, 08:54 UTC
Shanghai Yizhong's wholly-owned subsidiary Shanghai Youxi Chuang Pharmaceutical Technology received a drug clinical trial approval notice from China's National Medical Products Administration for its self-developed innovative drug YXC-001 (a trifunctional antibody fusion protein) for the treatment of advanced solid tumors.
Source: